Exousia Bio, Inc. (LMMY)
Exousia Bio, Inc. operates in the Education & Training Services industry of the Consumer Defensive sector, headquartered in Saint Petersburg, FL, US. The stock last traded at $0.40, up 0.00% on the session, giving a market capitalisation of $3.1M. On trailing twelve-month figures it carries a trailing P/E of -22.86, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Exousia Bio, Inc. is most often compared with the following Consumer Defensive names: